Johnson & Johnson’s vaccine, popular for its one-shot dose, is losing its steam. J&J is now scaling back production of the vaccine, writes Jared S. Hopkins and Peter Loftus for The Wall Street Journal.

The pharmaceutical giant paired up with its competitor Merck, after the Rahway, N.J.-based company was unsuccessful in its efforts to produce its own vaccine.

The two companies completed the final phases of manufacturing and production at a West Point plant. The doses from the Montgomery County site were rolled out specifically for people outside the U.S.

While still with millions of doses available, J&J’s success in vaccine manufacturing is falling by the wayside. It’s now terminated several manufacturing agreements.

“They were trying to do this the best way possible to meet global demand but all of those plans fell apart,” said supply-chain expert Prashant Yadav.

According to the CDC, only 19 million doses of the Johnson & Johnson shot have been administered, compared with 400 million of the Pfizer shot and 250 million of the Moderna version. The Wall Street Journal cites manufacturing issues causing limited availability and the risk of blood-clotting as the reasons for the shot’s decline in popularity.  

Manufacturing was stifled by delays in the arrival of vaccine ingredients and components. Now both J&J and Merck are filing for arbitration.  

Read more about the Johnson and Johnson vaccine production at its West Point plant in The Wall Street Journal.